| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Review |
Christopher P. Crum, MD, Division of Women’s and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115
Ronny Drapkin, MD, PhD, Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115
David Kindelberger, MD, Division of Women’s and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115
Fabiola Medeiros, MD, Division of Women’s and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115
Alexander Miron, PhD, Division of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115
Yonghee Lee, MD, Division of Women’s and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115
Reprint Requests: Christopher P. Crum, MD, Department of Pathology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, Tel: 617-732-5481, Fax: 617-264-5125, Email: ccrum{at}partners.org
Ovarian epithelial cancer is diagnosed in approximately 25,000 women yearly in the United States, accounting for approximately 12,500 deaths. Of these tumors, serous cancer is the most lethal, due to its capacity to spread beyond the reproductive tract and involve the peritoneal surfaces or distant organs. Conventional classification systems designate tumor origins principally on the location of the largest tumor. However, despite the fact that the largest tumors typically involve the ovaries, demonstrations of a precise starting point for these tumors, including precursor lesions, have been inconsistent. In recent years, a major effort to prevent serous cancer in genetically susceptible women with mutations in BRCA1 or BRCA2 has spawned the practice of prophylactic salpingo-oophorectomy. This practice has surprisingly revealed that many early cancers in these women arise in the fallopian tube, and further studies have pinpointed the distal (fimbrial) portion as the most common site of origin. Emerging studies that carefully examine the fallopian tubes suggest a high frequency of early cancer in the fimbria in unselected women with ovarian and peritoneal serous carcinoma, raising the distinct possibility that a significant proportion of these tumors have a fimbrial origin. The evidence for these discoveries and their relevance to serous cancer classification, early detection and prevention are addressed in this review. A model for pelvic serous cancer is proposed that takes into account five distinct variables which ultimately impact on origin and tumor distribution: (1) location of target epithelium, (2) genotoxic stress, (3) type of epithelium, (4) mitigating genetic factors, and (5) tumor spread pattern. Ultimately, this model illustrates the importance of identifying cancer precursors, inasmuch as these entities are useful as both surrogate endpoints for their respective malignancies in epidemiologic studies and natural targets for cancer prevention.
Key Words: BRCA, Fallopian tube neoplasms • Fimbria • Ovarian neoplasms • p53 • SEE-FIM • Serous carcinoma
This article has been cited by other articles:
|
|
 |
|
  A. A. Tone, H. Begley, M. Sharma, J. Murphy, B. Rosen, T. J. Brown, and P. A. Shaw Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma Clin. Cancer Res., July 1, 2008; 14(13): 4067 - 4078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Scholler, K. A. Lowe, L. A. Bergan, A. V. Kampani, V. Ng, R. M. Forrest, J. D. Thorpe, J. A. Gross, B. M. Garvik, R. Drapkin, et al. Use of Yeast-Secreted In vivo Biotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISA Clin. Cancer Res., May 1, 2008; 14(9): 2647 - 2655. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
